TFF Pharmaceuticals Hires Outcome Capital for Partnership and Licensing Evaluation

FORT WORTH, Texas, June 26, 2024 - TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a biopharmaceutical company at the clinical stage, has announced its collaboration with Outcome Capital. This partnership aims to explore potential corporate partnerships and licensing opportunities for TFF Pharmaceuticals’ products.

Dr. Harlan Weisman, CEO of TFF Pharmaceuticals, expressed satisfaction with the new collaboration. He emphasized the innovative nature and commercial potential of their leading clinical assets, TFF VORI and TFF TAC. Weisman noted that this collaboration with Outcome Capital, a reputable investment bank in the life sciences sector, will help identify meaningful partnerships or licensing deals to benefit shareholders.

Oded Ben-Joseph, Ph.D., MBA, Managing Partner of Outcome Capital, remarked on the significant progress TFF Pharmaceuticals has made. He highlighted the application of TFF’s formulation technology to create clinical-stage products that promise to enhance current care standards. Ben-Joseph looks forward to exploring opportunities to maximize the value of TFF Pharmaceuticals' Phase 2 assets.

TFF TAC is an inhaled dry powder form of tacrolimus, an immunosuppressive drug primarily used to prevent organ rejection post-transplantation. The oral form of tacrolimus, while effective, often leads to kidney toxicity, especially at high doses needed after lung transplants. TFF TAC aims to deliver the drug directly to the lungs, enhancing lung immunosuppression while reducing systemic exposure and associated toxicities. The inhaler for TFF TAC is user-friendly.

The ongoing Phase 2 trial for TFF TAC involves lung transplant patients who have kidney toxicity and require lower tacrolimus blood levels. The trial consists of two parts: a 12-week treatment period (Part A) and an optional safety extension period (Part B). Key trial endpoints include safety, tolerability (including kidney function), acute allograft rejection, and pharmacokinetics.

TFF Pharmaceuticals’ proprietary Thin Film Freezing (TFF) technology facilitates the conversion of existing compounds and new chemical entities into dry powder formulations with unique benefits. The TFF process creates dry powder particles ideal for inhalation and other administration routes, such as parenteral, nasal, oral, topical, and ocular. This method allows direct delivery to the target site, improving bioavailability, onset of action, safety, and efficacy. By delivering therapies directly to the lung, TFF powders can be administered at lower doses than oral drugs, reducing side effects. Laboratory tests indicate that TFF powders can deliver up to 75% of the dose to the deep lung. The TFF process avoids the use of heat, shear stress, or other potentially damaging forces, preserving the integrity of complex therapeutic components like fragile biologics. This technology enables the reformulation of these materials into stable, easily stored dry powders, enhancing the accessibility of therapeutics and vaccines globally. TFF technology can enhance traditional delivery methods and enable next-generation pharmaceutical products.

TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm utilizing patented rapid freezing technology to develop potent dry powder drug formulations for better efficacy, safety, and stability. Their versatile TFF technology platform can transform various drugs, including vaccines, small and large molecules, and biologics, into beneficial dry powders suitable for inhalation or topical delivery to the eyes, nose, and skin.